CP121635062 | AstraZeneca vaccine to remain authorized in Canada

CP122404571 | Quebec reports first blood clot death in woman who received AstraZeneca vaccine

CP124397371 | AstraZeneca recipients can get Moderna or Pfizer for second dose: NACI

CP123262421 | N.S. pauses use of AstraZeneca vaccine

CP123597771 | Second-dose choice likely for AstraZeneca recipients: Tam

CP120476771 | AstraZeneca vaccine's benefits vastly outweigh risks: Sharma

CP122830710 | New Brunswick reports blood clot death in connection with Oxford-AstraZeneca vaccine

CP123251321 | Ontario to get more than 250,000 AstraZeneca doses

CP122904771 | B.C. records first case of rare blood clot related to vaccine

CP123774871 | Ontario to resume AstraZeneca shots for COVID-19 as second dose

Placeline/People

City Vaughan

Country Canada

AstraZeneca blood clot risk remains low: Tam

Dr. Theresa Tam, Canada's chief public health officer, has explained why the National Advisory Committee on Immunization abruptly cancelled an expected announcement on Tuesday about its updated recommendations for the Oxford-AstraZeneca vaccine. Tam says the committee received some new data about the impact of COVID-19 variants of concern, and not because of any new information about the risk of blood clots that may be linked to the vaccine.

Source name:

Unique identifier: CP122017117

Legacy Identifier: n_Tam-NACI-Vaccine20210421T1430

Type: Video

Duration: 3m17s

Dimensions: 1920px × 1080px 143.31 MB

Usage rights: FOR ONE TIME USE ONLY. NO STORAGE FOR FUTURE USE.

Create Date: 4/21/2021 2:30:00 PM

Display aspect ratio: 16:9